Short Interest: ACCUREXA INCORPORATED (OTCMKTS:ACXA) Sellers Increased By 361.54% Their Shorts

November 23, 2016 - By Peter Erickson   ·   0 Comments

Short Interest: ACCUREXA INCORPORATED (OTCMKTS:ACXA) Sellers Increased By 361.54% Their Shorts

The stock of ACCUREXA INCORPORATED (OTCMKTS:ACXA) registered an increase of 361.54% in short interest. ACXA’s total short interest was 6,000 shares in November as published by FINRA. Its up 361.54% from 1,300 shares, reported previously. With 4,100 shares average volume, it will take short sellers 2 days to cover their ACXA’s short positions. The stock last traded at $0.55 per share. It is down 6.78% since April 21, 2016 and is downtrending. It has underperformed by 12.11% the S&P500.

Accurexa, Inc. is a development-stage company. The company has a market cap of $4.64 million. The Firm is focused on developing neurological therapies to be directly delivered into specific regions of the brain. It currently has negative earnings. The Firm is developing its ACX-31 program to deliver approximately two chemotherapy drugs, temozolomide in combination with biodegradable 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) locally to brain tumor sites.

ACXA Company Profile

Accurexa, Inc. (Accurexa), incorporated on August 29, 2012, is a development-stage company. The Firm is focused on developing neurological therapies to be directly delivered into specific regions of the brain. The Firm is developing its ACX-31 program to deliver approximately two chemotherapy drugs, temozolomide in combination with biodegradable 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) locally to brain tumor sites. Through its second development program, it is developing BranchPoint device that can deliver therapeutics through the radial deployment of a delivery catheter to large and anatomically complex brain targets through a single initial brain penetration. It is based on a neurosurgical delivery platform, which can enable approaches to neurological therapy and be modified for the delivery of a range of therapeutics, such as stem cells to treat neurodegenerative diseases, chemotherapeutics to brain tumors and gene therapy vectors.

More notable recent Accurexa Inc (OTCMKTS:ACXA) news were published by: Bizjournals.com which released: “It’s not brain surgery — well it is for Accurexa and Dr. Daniel Lim” on August 08, 2014, also Prnewswire.com with their article: “DelMar Pharmaceuticals and Accurexa to Collaborate in the Development of a …” published on September 07, 2016, Marketwired.com published: “”NEW TO THE STREET’s” October Line-Up Broadcast on FOX Business — Accurexa …” on October 03, 2016. More interesting news about Accurexa Inc (OTCMKTS:ACXA) were released by: Marketwired.com and their article: “”NEW TO THE STREET” Broadcasting on FOX Business, October 30, 2016, 1 PM …” published on October 25, 2016 as well as Finance.Yahoo.com‘s news article titled: “DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2017 Financial …” with publication date: November 14, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Peter Erickson


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>